keyword
MENU ▼
Read by QxMD icon Read
search

Genitourinary cancer,melanoma

keyword
https://www.readbyqxmd.com/read/27843591/descriptive-statistical-analysis-of-a-real-life-cohort-of-2419-patients-with-brain-metastases-of-solid-cancers
#1
Anna S Berghoff, Sophie Schur, Lisa M Füreder, Brigitte Gatterbauer, Karin Dieckmann, Georg Widhalm, Johannes Hainfellner, Christoph C Zielinski, Peter Birner, Rupert Bartsch, Matthias Preusser
AIM: We provide a descriptive statistical analysis of baseline characteristics and the clinical course of a large real-life cohort of brain metastases (BM) patients. METHODS: We performed a retrospective chart review for patients treated for BM of solid cancers at the Medical University of Vienna between 1990 and 2011. RESULTS: We identified a total of 2419 BM patients (50.5% male, 49.5% female, median age 59 years). The primary tumour was lung cancer in 43...
2016: ESMO Open
https://www.readbyqxmd.com/read/27742175/mucosal-melanomas-in-the-racially-diverse-population-of-california
#2
Lisa Altieri, Michael K Wong, David H Peng, Myles Cockburn
BACKGROUND: Mucosal melanomas are rare, poorly understood neoplasms without a consensus standard of care. OBJECTIVE: We sought to define mucosal melanoma tumor characteristics and the racial/ethnic attributes of patients with mucosal melanomas. METHODS: We analyzed 130,920 cutaneous melanomas and 1919 mucosal melanomas recorded in the population-based California Cancer Registry from 1988 to 2013. RESULTS: Although only 1% of melanomas occurring in nonHispanic whites were mucosal, other racial/ethnic groups had a higher proportion of mucosal melanomas (15% for Asian/Pacific Islanders, 9% for nonHispanic blacks, and 4% for Hispanics)...
October 11, 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27517637/combination-immunotherapy-in-genitourinary-malignancies
#3
Jean Hoffman-Censits, Lindsay Wilde
PURPOSE OF REVIEW: Combination immunotherapy has already shown promise in several tumor types, such as melanoma and nonsmall cell lung cancer, and studies are ongoing to evaluate this approach in other malignancies. Trials such as these will only continue to expand as additional immune therapies are shown to have efficacy as single agents in cancer. The purpose of this review is to outline the current landscape of immunotherapy in genitourinary cancer, and to highlight ongoing and pending combination immunotherapy trials in bladder, kidney, and prostate cancers...
November 2016: Current Opinion in Urology
https://www.readbyqxmd.com/read/27317515/epidemiology-of-genitourinary-melanoma-in-the-united-states-1992-through-2012
#4
Ritva Vyas, Cheryl L Thompson, Homayoun Zargar, Jacqueline Selph, Meg R Gerstenblith
BACKGROUND: Primary melanoma arising in the genitourinary tract is rare and poorly characterized. OBJECTIVES: We sought to describe the epidemiology of genitourinary melanoma in the United States. METHODS: Incident case and population data were obtained for genitourinary melanoma from the Surveillance, Epidemiology, and End Results 13 Registries Database between 1992 and 2012. RESULTS: A total of 817 patients with genitourinary melanoma were identified; most cases occurred in the vulva...
July 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27183027/immunotherapy-for-genitourinary-cancer-state-of-the-art-and-new-perspectives
#5
Carlo Cattrini, Chiara Dellepiane, Alessia Cavo, Giulia Buzzatti, Francesco Tolomeo, Carlo Messina, Francesco Boccardo
In the last few years, cancer immunotherapy has changed the natural history and treatment strategies of a number of solid tumors, including melanoma and lung cancer. The anti-PD-1 nivolumab showed a survival benefit compared with everolimus in the second-line treatment of renal cell carcinoma, resulting in a radical shift in perspective in the treatment of this neoplasia and suggesting a new scenario beyond tyrosine kinase inhibitors. Checkpoint inhibitors might also improve the treatment of urothelial cancer, considering the promising results achieved so far and the relatively low efficacy of currently available treatments...
August 2016: Anti-cancer Drugs
https://www.readbyqxmd.com/read/26923782/blocking-immune-checkpoints-in-prostate-kidney-and-urothelial-cancer-an-overview
#6
REVIEW
Angela K B Alme, Beerinder S Karir, Bishoy M Faltas, Charles G Drake
Despite a long history of immunotherapeutic approaches to treatment, most genitourinary malignancies are not cured by existing immunotherapy regimens. More recently, cell surface molecules known as immune checkpoints have become the focus of efforts to develop more effective immunotherapies. Interactions between these molecules and their ligands inhibit the proliferation and function of tumor-specific lymphocytes. A monoclonal antibody blocking 1 of these checkpoints was approved for the treatment of metastatic melanoma and is now being tested in other malignancies...
April 2016: Urologic Oncology
https://www.readbyqxmd.com/read/26889142/liver-resection-for-non-colorectal-liver-metastases-standards-and-extended-indications
#7
REVIEW
Ulf Kulik, Frank Lehner, Hüseyin Bektas, Jürgen Klempnauer
BACKGROUND: Due to the uncertain benefit of liver resection for non-colorectal liver metastases (NCLM), patient selection for surgery is generally difficult. Therefore, the aim of this article was to propose standard and extended indications for liver resection in this heterogeneous disease collective. METHODS: Review of the literature. RESULTS: The myriad of biologically different primary tumor entities as well as the mostly small and retrospective studies investigating the benefit of surgery for NCLM limits the proposal of general recommendations...
December 2015: Viszeralmedizin
https://www.readbyqxmd.com/read/26739672/primary-genitourinary-melanoma-epidemiology-and-disease-specific-survival-in-a-large-population-based-cohort
#8
Alejandro Sanchez, Dayron Rodríguez, Christopher B Allard, Seth K Bechis, Ryan J Sullivan, Caroline E Boeke, David Kuppermann, Jed-Sian Cheng, Glen W Barrisford, Mark A Preston, Adam S Feldman
BACKGROUND: Primary genitourinary (GU) melanoma is a rare disease, which is poorly characterized. OBJECTIVE: To examine clinical characteristics and survival outcomes of primary GU melanoma among men and women. DESIGN, SETTING, AND PARTICIPANTS: Retrospective study using the Surveillance, Epidemiology, and End Results database (1973-2010) was used to identify primary GU melanoma cases by tumor site and histology codes. We examined associations of GU melanoma with demographic, clinical, and pathologic characteristics, as well as disease-specific survival (DSS)...
April 2016: Urologic Oncology
https://www.readbyqxmd.com/read/26341625/liver-metastases-from-non-gastrointestinal-non-neuroendocrine-tumours-review-of-the-literature
#9
REVIEW
Flavia Neri, Giorgio Ercolani, Paolo Di Gioia, Massimo Del Gaudio, Antonio Daniele Pinna
Liver resection is integrated in the oncological surgical management of metastatic gastrointestinal and neuroendocrine tumours. However, the good prognosis reached in these cases has not been obtained for metastatic tumours of other histological types. In this review, we analysed the published case reports and series of hepatectomies in patients with metastatic breast cancer, melanoma, sarcoma, genitourinary tumours, pulmonary and adrenocortical tumours. From the reported data the surgical resection of oligometastases yields good results in terms of improved survival, in particular when the disease-free time period is longer than 1 year...
September 2015: Updates in Surgery
https://www.readbyqxmd.com/read/26086854/differential-activity-of-nivolumab-pembrolizumab-and-mpdl3280a-according-to-the-tumor-expression-of-programmed-death-ligand-1-pd-l1-sensitivity-analysis-of-trials-in-melanoma-lung-and-genitourinary-cancers
#10
Luisa Carbognin, Sara Pilotto, Michele Milella, Vanja Vaccaro, Matteo Brunelli, Anna Caliò, Federica Cuppone, Isabella Sperduti, Diana Giannarelli, Marco Chilosi, Vincenzo Bronte, Aldo Scarpa, Emilio Bria, Giampaolo Tortora
BACKGROUND: The potential predictive role of programmed death-ligand-1 (PD-L1) expression on tumor cells in the context of solid tumor treated with checkpoint inhibitors targeting the PD-1 pathway represents an issue for clinical research. METHODS: Overall response rate (ORR) was extracted from phase I-III trials investigating nivolumab, pembrolizumab and MPDL3280A for advanced melanoma, non-small cell lung cancer (NSCLC) and genitourinary cancer, and cumulated by adopting a fixed and random-effect model with 95% confidence interval (CI)...
2015: PloS One
https://www.readbyqxmd.com/read/26049692/trends-in-adjuvant-and-neoadjuvant-radiotherapy-for-cancer-treatment-from-1973-to-2011
#11
Daniel Le Bui, James Byunghoon Yu
PURPOSE: Cancer care is becoming increasingly complicated, in particular with the integration of radiation and surgery. Institutions may need to increase coordination between multidisciplinary clinical teams to optimize patient care. This study examines historical trends in adjuvant and neoadjuvant radiation therapy (ANRT) before or after cancer-directed surgery to identify disease sites that may benefit from coordinated care. METHODS: The Surveillance, Epidemiology, and End Results database was queried to identify patients with bladder cancer; breast cancer; cervical cancer; colorectal cancer; kidney cancer; cancer of the lung, bronchus, and pleura; lymphoma; melanoma; cancer of the oral cavity and pharynx; ovarian cancer; pancreatic cancer; prostate cancer; thyroid cancer; and uterine cancer from 1973 to 2011...
May 2015: Cancer Journal
https://www.readbyqxmd.com/read/25949877/tumor-stroma-and-chemokines-control-t-cell-migration-into-melanoma-following-temozolomide-treatment
#12
Kar Wai Tan, Maximilien Evrard, Muly Tham, Michelle Hong, Caleb Huang, Masashi Kato, Armelle Prevost-Blondel, Emmanuel Donnadieu, Lai Guan Ng, Jean-Pierre Abastado
The infiltration of T lymphocytes within tumors is associated with better outcomes in cancer patients, yet current understanding of factors that influence T-lymphocyte infiltration into tumors remains incomplete. In our study, Temozolomide (TMZ), a chemotherapeutic drug used to treat metastatic melanoma, induced T-cell infiltration into transplanted melanoma and into genitourinary (GU) tumors in mice developing spontaneous melanoma. In contrast, TMZ treatment did not increase T-cell infiltration into cutaneous tumors, despite similar increases in the expression of the (C-X-C) chemokines CXCL9 and CXCL10 in all sites after TMZ exposure...
February 2015: Oncoimmunology
https://www.readbyqxmd.com/read/25674547/is-2-deoxy-2-18-f-fluoro-d-glucose-pet-ct-acquisition-from-the-upper-thigh-to-the-vertex-of-skull-useful-in-oncological-patients
#13
B Salvatore, M G Caprio, R Fonti, D D'Amico, F Fraioli, M Salvatore, L Pace
AIM: To assess whether performing routinely 2-deoxy-2-[(18)F]fluoro-D-glucose PET/CT ((18)FDG PET/CT) scan from the upper thigh to the vertex of skull is clinically relevant. MATERIALS AND METHODS: 3502 (1634 female; mean-age 60+16) consecutive patients undergoing (18)FDG PET/CT were retrospectively analyzed. Patients were divided in 10 groups according to primary malignancy. Chi-square analysis was used to assess differences among proportions. A p value < 0...
January 2015: Translational Medicine @ UniSa
https://www.readbyqxmd.com/read/25148767/the-benefits-of-liver-resection-for-non-colorectal-non-neuroendocrine-liver-metastases-a-systematic-review
#14
REVIEW
Timothy L Fitzgerald, Jason Brinkley, Shannon Banks, Nasreen Vohra, Zachary P Englert, Emmanuel E Zervos
PURPOSE: Defining the benefits of resection of isolated non-colorectal, non-neuroendocrine (NCRNNE) liver metastases is difficult. To better understand the survival benefit in this group of patients, we conducted a systematic review of the previous literature. METHODS: Medline, Web of Knowledge, and manual searches were performed using search terms, such as "liver resection" and "primary tumor." Inclusion criteria were year>1990, >five patients, and median survival reported or derived...
December 2014: Langenbeck's Archives of Surgery
https://www.readbyqxmd.com/read/25092813/cancer-immunotherapy-highlights-from-the-2014-asco-meeting
#15
Lauren C Harshman, Charles G Drake, Jennifer A Wargo, Padmanee Sharma, Nina Bhardwaj
The promise of cancer immunotherapy was validated officially in March 2011 when the FDA approved Yervoy (ipilimumab; Bristol-Myers Squibb) for the treatment of unresectable or metastatic melanoma. The approval was based on results of a randomized, double-blind clinical trial establishing that ipilimumab (a humanized anti-CTLA-4 monoclonal antibody) treatment extended the overall survival of patients with advanced melanoma. CTLA-4 is a member of the so-called family of checkpoint regulators, which are expressed on immune cells that activate or inhibit an immune response...
August 2014: Cancer Immunology Research
https://www.readbyqxmd.com/read/24521777/acute-rejection-t-cell-depleting-antibodies-and-cancer-after-transplantation
#16
Wai H Lim, Robin M Turner, Jeremy R Chapman, Maggie K M Ma, Angela C Webster, Jonathan C Craig, Germaine Wong
BACKGROUND: Systemic inflammatory response has been shown to play a vital role in carcinogenesis and tumor progression. Acute rejection is a systemic inflammatory state and may share a common casual pathway for cancer development after transplantation. The increased burden of immunosuppression used in the treatment of acute rejection, particularly the use of T-cell-depleting antibody may further heighten the risk of cancer development. We aimed to determine the association between acute rejection, T-cell-depleting antibody use and cancer risk after kidney transplantation...
April 27, 2014: Transplantation
https://www.readbyqxmd.com/read/24474656/insurance-status-and-distant-stage-disease-at-diagnosis-among-adolescent-and-young-adult-patients-with-cancer-aged-15-to-39-years-national-cancer-data-base-2004-through-2010
#17
Anthony S Robbins, Catherine C Lerro, Ronald D Barr
BACKGROUND: The percentage of adolescent and young adult (AYA) patients with cancer (those aged 15-39 years) diagnosed at a distant stage of disease did not significantly change between 1975 and 2004. It has been hypothesized that a lack of health insurance may be a significant risk factor for a diagnosis of distant-stage disease among AYA patients, but to the authors' knowledge this has not been examined in a national sample. METHODS: The National Cancer Data Base, a hospital-based cancer registry, was used to obtain data regarding incident cancer cases among patients aged 15 years to 39 years who were diagnosed between 2004 and 2010...
April 15, 2014: Cancer
https://www.readbyqxmd.com/read/24055405/penile-metastases-of-rectal-adenocarcinoma
#18
Z Persec, J Persec, T Sovic, D Rako, I Savic, D K Marinic
INTRODUCTION: Penile metastases are very rare and arise most frequently from genitourinary cancers. Penile metastases from rectal adenocarcinoma are less common and only 50 or so cases have been reported. CASE PRESENTATION: We present a 43-year-old man with penile metastases from a rectal adenocarcinoma. Two years before admittance to our department, abdomino-perineal resection of the rectum (Miles operation) was performed for a Dukes B (T3N0M0) rectal adenocarcinoma; the surgical resection margins wee negative...
February 2014: Journal of Visceral Surgery
https://www.readbyqxmd.com/read/23338728/folic-acid-supplementation-and-cancer-risk-a-meta-analysis-of-randomized-controlled-trials
#19
REVIEW
Xianhui Qin, Yimin Cui, Lin Shen, Ningling Sun, Yan Zhang, Jianping Li, Xin Xu, Binyan Wang, Xiping Xu, Yong Huo, Xiaobin Wang
There are growing data and a continuing controversy over the effect of folic acid supplementation on cancer risk. We conducted a meta-analysis based on up-to-date published relevant randomized trials to further examine this issue. Relative risk (RR) was used to measure the effect of folic acid supplementation on risk of cancer using a random-effects model. Overall, folic acid supplementation had no significant effect on total cancer incidence (13 trials, n = 49,406, RR = 1.05; 95% CI: 0.99-1.11, p = 0...
September 1, 2013: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/23292836/leptomeningeal-metastases-from-genitourinary-cancer-the-university-of-texas-md-anderson-cancer-center-experience
#20
Shlomit Yust-Katz, Samuel Mathis, Morris D Groves
Leptomeningeal metastasis (LM) most commonly arise from breast and lung cancers, and melanoma. Genitourinary cancer (including ovarian, prostate, uterine kidney and bladder) rarely cause LM, with only case reports published. The aims of the study were to describe cases of patients with Genitourinary cancer and Leptomeningeal metastasis, to estimate its prevalence and describe its behavior and outcome. We queried the MD Anderson database for patients with LM and genitourinary cancer between 1978 and 2011. The files of all patients with genitourinary cancer and leptomeningeal disease were retrospectively reviewed...
March 2013: Medical Oncology
keyword
keyword
89308
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"